Seer to Present at the Cowen 42nd Annual Health Care Conference
Seer, a life sciences company specializing in proteomics, has announced its virtual participation in the Cowen 42nd Annual Health Care Conference scheduled for March 8, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer, a life sciences company specializing in proteomics, has announced its virtual participation in the Cowen 42nd Annual Health Care Conference scheduled for March 8, 2022. The company's management will engage in a fireside chat at 11:50 a.m. Pacific Time. Interested investors can access a live webcast on Seer’s investor website, with an archived replay available afterward. Seer’s Proteograph Product Suite enables deep proteomic analysis efficiently and is designed for research use only, aiming to enhance laboratory capabilities.
Details
News Market Reaction – SEER
The recorded move for SEER in the trading session of this news was -7.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating virtually in the upcoming Cowen 42nd Annual Health Care Conference.
Seer’s management is scheduled to participate in a fireside chat on Tuesday, March 8 at 11:50 a.m. Pacific Time / 2:50 p.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.
About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact
Carrie Mendivil
investor@seer.bio
Media Contact
Karen Possemato
pr@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.